Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 135Carcinoma, Hepatocellular 81Neoplasms 53Small Cell Lung Carcinoma 51Breast Neoplasms 50Lung Neoplasms 45Triple Negative Breast Neoplasms 41Colorectal Neoplasms 39Melanoma 38Carcinoma, Transitional Cell 37Urinary Bladder Neoplasms 33Neoplasm Metastasis 32Carcinoma, Renal Cell 30Ovarian Neoplasms 20Uterine Cervical Neoplasms 19Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Head and Neck Neoplasms 15Liver Neoplasms 14Prostatic Neoplasms 13Glioblastoma 12Solid Tumors 11Recurrence 11Sarcoma 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Lymphoma 9Kidney Neoplasms 9Endometrial Neoplasms 9Mesothelioma, Malignant 8

Interventions

Lenalidomide 17Dexamethasone 15Calcium Dobesilate 8daratumumab 5dexamethasone acetate 4dexamethasone 21-phosphate 4carfilzomib 4auricularum 4Melphalan 4Leflunomide 3Curcumin 3isatuximab 2iberdomide 2elotuzumab 2Peripheral Blood Stem Cell Transplantation 2PVX-410 vaccine 2Denosumab 2Cyclophosphamide 2Bortezomib 2siltuximab 1selinexor 1sargramostim 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × atezolizumab × Clear all
NCT02784483 2020-03-03

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Yale University

Phase 1 Terminated
2 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡